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Abstract
Background: Though long known to affect smooth muscle biology, recent studies indicate that phosphodiesterase 5 (PDE5)
is also expressed in myocardium. Recognizing that the regulation of PDE5 in hypertrophy is not well understood, we
assessed the response of PDE5 expression and the level of cGMP-dependent kinase I (cGKI) in the left and right ventricles of
feline hypertrophy models.
Methodology/Principal Findings: Using a cDNA library of feline aortic smooth muscle cells, we identified and cloned PDE5
cDNA for the first time in this species. The sequence shares 98% identity with its human orthologue at the amino acid level.
E. coli expression of the cloned allele allowed selection of antibodies with appropriate specificity, facilitating the analysis of
PDE5 expression in feline models created by selective proximal aortic (Ao) or pulmonary artery (PA) banding that resulted in
hypertrophy of the left ventricle (LV) and right ventricle (RV), respectively. We demonstrated that PDE5 expression
responded differentially with a decreased expression in the LV and an increased expression in the RV in the Ao-banded
model. Similarly, in the PA-banded model, LV showed reduced expression while the RV expression was unaltered. In
addition, the expression of cGKI was significantly decreased in the RV of Ao-banded group, correlating inversely with the
increase in PDE5 expression.
Conclusions/Significance: The differential regulation of PDE5 and cGKI expression suggests that the mechanisms involved
in hypertrophy could be different in RV vs. LV. Reciprocal PDE5 and cGKI expression in the RV of Ao-banded model suggests
functional significance for PDE5 up-regulation.
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Introduction
PDE5 is a cGMP specific phosphodiesterase that converts
cGMP to GMP. By hydrolyzing cGMP, PDE5 regulates
intracellular cGMP levels that affect the tone of vascular smooth
muscle, where PDE5 is abundantly expressed [1,2]. Cyclic GMP
exerts its functions through downstream effectors, including
protein kinase G (PKG) and cyclic nucleotide-gated channels
[3]. The PDE5 enzyme is a homodimer with an allosteric cGMP-
binding site and a serine phosphorylation site in the N-terminal
regulatory domain of each subunit. The binding of cGMP to the
allosteric site activates PDE5 by increasing the binding affinity of
cGMP to the catalytic site in the C-terminal catalytic domain.
Phosphorylation of the serine residue by cGKI was shown to
further enhance the substrate binding affinity to the catalytic site
[4]. The regulation of PDE5 transcription is thought to be through
sp-1 and AP2 transcription factors [5].
In animal models and patients with pulmonary hypertension,
PDE5 levels in the smooth muscle are elevated, leading to reduced
cellular cGMP concentrations that causes abnormal regulation of
vasodilatory mechanisms [6]. Inhibition of PDE5 with sildenafil
has been shown to reduce pulmonary vasoconstriction, thereby
alleviating right ventricular overload and remodeling [7,8,9].
Although myocardial PDE5 expression has been reported in
humans and other species, the function of myocardial PDE5
expression is not well understood [2]. PDE5 inhibitors have been
used in a number of studies to discern the functions of the enzyme
in cardiac hypertrophy and heart failure [10][9,11,12,13,14,15].
However, the results show that PDE5 inhibition is beneficial under
certain conditions but not others [9,12,13,14]. Differential
regulation of cGMP/cGKI signaling pathway in the RV vs. LV
under hypertrophic conditions is thought to affect the effectiveness
of strategies to limit pathological myocardial remodeling through
PDE5 inhibition [16].
Because PDE5 is critically involved in the regulation of cellular
cGMP levels, determination of the abundance of PDE5 in RV and
LV could provide further assessments of the cGMP/cGKI
functions in RV and LV respectively in response to hypertrophic
stimulations, since tissue PDE5 expression directly impacts the
total cellular PDE5 activity. In this study, we identified and cloned
PDE5 cDNA for the first time in feline. An antibody that
recognizes the expressed protein was used to examine PDE5
expression levels in both the left and the right ventricles of two
feline cardiac hypertrophy models relative to a normal control
group. By comparing RV and LV PDE5 expression in response to
the hypertrophic conditions, the existence of a chamber-depen-
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e19922dent regulation could be assessed. Expression of cGKI, a
downstream effector of cGMP, was also analyzed to further
examine the impact of PDE5 on the cGMP signaling pathway.
Results
Identification and Isolation of a Feline cDNA
Homologous to Human PDE5
Feline hypertrophy models have been utilized to mimic disease
states of human heart failure [17,18]. However, the gene encoding
PDE5 in feline was not previously identified. To accurately
characterize the molecular mechanisms of PDE5 involvement in
hypertrophy, the availability of the sequence information becomes
important. Based on the current knowledge of PDE5 tissue
distribution, we generated a cDNA library with cells isolated from
aortic smooth muscle. Using primers hybridizing to the highly
homologous regions of PDE5 among different species, we
amplified DNA fragments from the cDNA library and sequenced
these fragments. BLAST (Basic Local Alignment Search Tool
[19]) analysis showed that these cDNA fragments were highly
similar to human PDE5 cDNA. They correspond to a region of
human PDE5 cDNA that began near the start codon and
extended beyond the stop codon. By 59-RACE, we were able to
obtain the missing 59- end of the feline cDNA and to assemble an
ORF encoding a polypeptide of 824 amino acids. The nucleotide
sequence was deposited at GenBank (HQ446880). Multiple
sequence alignment results using Clustal W [20] showed that the
feline ORF shared 98% identity with the human orthologue at the
amino acid level, the highest among the known PDE5 sequences
(Fig. 1a). Using the Simple Modular Architecture Research Tool
[21,22], the protein was predicted to contain both GAF and the
catalytic domains (Fig. 1b). These domains are highly conserved
among all the known PDE5s. At the N-terminus, the feline PDE5
ORF shared the highest similarity with splice variant 3 of human
PDE5A (Fig. 1c).
Detection of PDE5 Activities in Cell Extracts Expressing
the Isolated cDNA Allele
To verify that the isolated cDNA encodes the feline PDE5, we
cloned the entire ORF into pSNAP-tag(T7), under the control of
T7 promoter, to obtain plasmid pPDE5-T7 that allows the
expression of the cDNA in E. coli. After inducing the cultures of
transformed BL21-AI strains with 0.1% arabinose, whole cell
extracts were made from strains carrying either pPDE5-T7, or the
empty vector pSNAP-tag (T7) as a control. When analyzed by
immunoblot using a rabbit polyclonal antibody against human
PDE5, a protein band migrating close to the predicted molecular
weight of 93.7 kDa was detected only in the extract made from
cells carrying pPDE5-T7 (Figure 2a, lane 4), but not in extract
from cells carrying pSNAP-tag(T7) (Fig. 2a, lane 3). Coomassie
blue staining of the gel showed that there was no obvious protein
degradation in either sample (Figure 2a, lanes 1 and 2). These data
showed that pPDE5-T7 expressed a feline protein that was
specifically recognizable by an anti-human PDE5 antibody.
To confirm that the expressed protein was PDE5, a cGMP
specific phosphodiesterase, we measured cGMP hydrolysis activity
of the cell extracts in the presence or absence of a known PDE5
inhibitor, MY5445. As shown in Figure 2b, extracts from cells
carrying pPDE5-T7 showed PDE activity toward cGMP.
Furthermore, this PDE activity was inhibited by 30% when
MY5445 was included in the reaction mixture. Thus, the isolated
cDNA encodes a feline PDE5 allele and its translated protein
product can be recognized by an anti-human PDE5 antibody.
Expression of PDE5 and Detection of PDE Activity in
Feline Cardiac Tissues
To assess the presence of PDE5 in feline cardiac tissue, we
carried out immunohistochemical (IHC) staining on paraffin
sections of RV from the control group. As shown in Figure 3, a
section incubated with antibody against PDE5 produced positive
staining in cardiac myocytes with characteristic striation (Fig. 3A)
while a consecutive section processed in the same manner but
omitted the primary antibody did not display positive staining
(Fig. 3b). This data demonstrated the presence of PDE5 in feline
cardiac myocytes as previously observed in human specimens
[12,23]. To confirm the presence of PDE5 in these samples, we
then measured PDE activity in whole cell extracts made from both
RV and LV tissues of the same group of animals. Figure 4 showed
that PDE activity was detected in both the RV and the LV tissue
samples. Furthermore, addition of MY5445, a PDE5 inhibitor, led
to a significant reduction of the PDE activity, by 56% in the RV
and 53% in the LV. This result strongly suggested that a large
portion of the measured PDE activity was that of PDE5, thus
confirming the immunofluorescence data.
Establishment of Feline Hypertrophy Models
Feline PA- and Ao-banded models were created to simulate the
hypertrophy of the right ventricle (RV) or left ventricle (LV)
associated with pulmonary or systemic hypertension, respectively.
These models facilitated the study of PDE5 expression under the
hypertrophy conditions. A total of 12 animals in 3 groups, i.e.
Control, PA-banded and Ao-banded, were used. All tissue samples
but one were collected after one month of banding. Tissue samples
from the age-matched control group were collected at the same
time. One PA-banded sample was collected after 2 month of
banding. None of the animals included in these studies manifested
overt severe failure with ascites, pulmonary edema, lethargy or
cyanosis. Changes in cardiac morphology induced after one month
of Ao-banding or PA-banding are presented in Table 1 along with
analogous measurements in age-matched non-banded controls.
Both Ao- and PA-banding resulted in significant increases in the
heart weight to body weight ratio. In the Ao-banded animals at
one-month, echocardiography revealed a substantial increase in
the thickness of the intraventricular septum and the left ventricular
posterior wall with smaller, but significant increases in right
ventricular free wall thickness and left ventricular end-diastolic
dimension. These changes were associated with a marked increase
in the estimated LV mass and an insignificant decrease in left
ventricular fractional shortening. In the PA-Banded animals at
one-month, there was a substantial thickening of the right
ventricular free wall, but no other significant changes. The data
shows that increased resistance to ventricular outflow produced
load-induced hypertrophy of the relevant chamber. Although we
did not directly measure pulmonary artery pressures, the
significant increase in right ventricular wall thickness observed in
the animals with Ao-banding indirectly suggests that elevated
pulmonary pressures were present in this model.
Altered PDE5 Expression Levels in the Hypertrophy
Models
To examine the expression level of PDE5, homogenates of RV
and LV tissues from the control, PA- and Ao-banded animal
groups were prepared and PDE5 protein content in these samples
were assessed by immunoblotting, using the anti-human PDE5
antibody that recognized feline PDE5 expressed in E. coli
(Figure 5a and 5b). GAPDH levels in these samples were also
measured as an internal control of total protein content. The
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densitometry, was then normalized to the GAPDH expression
level, and the average expression level of each group (n=4) was
calculated (Figure 5c and 5d). As shown in Figure 5c and 5d,
compared with control group, average PDE5 expression was
reduced by 39% in the LV (p,0.023), but increased by 61% in the
RV (p,0.05) of Ao-banded animals. Similarly, average PDE5
expression was reduced by 32% in the LV (p,0.016) of PA-
banded animals. However, no statistically significant change in
PDE5 expression in the RV of PA-banded animals was detected,
in contrast to the RV of Ao-banded animals. These results showed
that PDE5 expression responded differently in RV and LV to
hypertrophy condition, and the response was also distinctive in the
different hypertrophy models.
Differential Expression of cGKI in Feline Hypertrophy
Models
Recognizing that cyclic GMP dependent kinase I (cGKI) is a
major downstream effector of cGMP, we examined the expression
levels of cGKI in the same sets of tissue samples by immunoblot-
ting, using an anti-cGKI antibody (Figure 6a and 6b). After
normalizing to GAPDH, the average expression level of each
group (n=4) was calculated and shown in Figure 6c and 6d. In
Ao-banded animals, we observed no detectable change of cGKI
abundance in the LV, but a 32% reduction of cGKI was observed
in the RV (p,0.027), compared to the control group. In the PA-
banded group, no statistically significant change in cGKI
expression level was observed in either the LV or the RV. Our
data thus indicate that cGKI response to Ao-banding is also
different in RV and LV, with a reciprocal relationship between
PDE5 (up) and cGKI (down) only observed in the RV.
Furthermore, cGKI expression and PDE5 expression patterns
appear uncoupled in PA-banded animals.
Discussion
In this study, we investigated the regulation of PDE5 expression
in LV and RV of Ao- and PA-banded feline hypertrophy models. A
Figure 1. Sequence and Structural features of feline PDE5. (a) Similarity between feline PDE5 and PDE5s from other species. The feline PDE5
sequence was obtain from the translation of the cloned cDNA sequence. Sequences of PDE5 from other species were obtained from GenBank. Multi-
sequence alignments were calculated using Clustal W. The % identities between feline and other species are in bold. (b) Domain structure of the
feline PDE5 protein. GAF indicates cGMP binding domain, and HDc the phosphohydrolase catalytic domain. Structure prediction was performed
using the SMART software. (c) Alignment of protein sequences from the N-terminal region of feline and human PDE5 variants. The shaded area
indicates identical residues and the residues in feline PDE5 that are different from those of human variants are noted with asterisks. The start codons
are in bold faces and amino acid residue numbers are indicated.
doi:10.1371/journal.pone.0019922.g001
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sequenced. The protein shared 98% sequence identity with its
human counterpart and was highly conserved structurally. The
difference between the feline and human PDE5 was primarily in the
59- end region, while the regions corresponding to the regulatory
and catalytic domains of the human PDE5 were nearly identical.
The feline PDE5 cDNA was cloned and expressed in E. coli to allow
the identification of antibodies that specifically recognize the feline
PDE5 protein. This permitted elucidation of chamber-specific
responsesintheregulationofPDE5expressiontopressureoverload.
In humans, there are three PDE5 isozymes, A1, A2, and A3, due
toalternativesplicingofthesametranscript[5].Theclonedputative
feline PDE5 is most similar to the human PDE5-A3, which has the
shortest N-terminal region (see Figure 1). Several studies have
shown that the splicing process for PDE5 could be tissue type
dependent [5,24]. In this regard, our data indicate that feline
smooth muscle cells express the A3 variant. Expression of the
putative feline PDE5 in E. coli allowed us to measure its enzyme
activity and to screen for antibodies that recognize this protein. By
immunoblotting, a polyclonal antibody against the human PDE5
was shown to recognize the putative feline PDE5 protein
specifically. It is worth noting that since this antibody cross-reacted
with the shortest form of PDE5, A3, it is unlikely to distinguish
among the three different variants. Therefore, the protein we
examined in feline cardiac tissue with this antibody could be any
isoform, or a combination of multiple isoforms of PDE5.
MY5445 is a PDE5 specific inhibitor used in many studies to
selectively inhibit the enzyme [25,26,27]. However, MY5445 has
reduced potency in inhibiting cGMP-hydrolysis in non-mammalian
system for reasons that remain unclear [28]. In our study, a
significant but incomplete inhibition of enzyme activity was
observed when extracts made from E. coli expressing the feline
PDE5 cDNA were used. The level of inhibition was almost doubled
when feline cardiac tissue extracts were used instead of bacterial
extracts. This suggests that proper post-translational modification
and folding of PDE5 is important for the inhibitor action.
Phosphorylation of PDE5 was reported to increase binding affinity
of Tadalafil to the catalytic site, which could lead to increased
potency of the inhibitor [29]. The N-terminal phosphorylation site
in PDE5 is conserved from human to feline. However, it is unlikely
that the protein expressed in E. coli will be properly phosphorylated.
Thus, the lack of adequate post-translational modification, or
proper folding, both could contribute to the reduced inhibition
efficiency of MY5445 against the E. coli expressed PDE5.
Nevertheless, the near identical sequence to human PDE5, the
cross-reactivity to the anti-human PDE5 antibody and the presence
of MY5445 inhibitable phosphodiesterase activity against cGMP
demonstrated that the cloned cDNA encodes feline PDE5.
Despite the great versatility and utility of rodent models, cardiac
excitation-contraction coupling and contractile reserve dynamics
in rodents differ from those of large mammals [30]. In addition,
cardiovascular and total body metabolism is also different between
small and large mammals [31]. Furthermore, small molecules may
not achieve the same effect when tested in different species
[32,33]. Most relevant for our studies, we observed differences in
our comparison of PDE5 cDNA primary structures across species.
Figure 2. Immunoblotting and enzyme activity measurement of feline PDE5 expressed in E. coli. (a) Immunoblot analysis and coomassie
blue staining of whole cell extracts made from E. coli cells carrying feline PDE5 expression plasmid pT7-PDE5 or a control vector pSNAP-tag(T7). Lanes
1 and 3 are extracts from cells carrying pSNAP-tag(T7). Lanes 2 and 4 are extracts from cells carrying pT7-PDE5. Lanes 1 and 2 are Coomassie blue
staining of the gel. Lanes 3 and 4 are immunoblot using an anti-human PDE5 antibody. (b) Measurement of PDE5 activity. PDE activity of the extracts
from cells carrying pT7-PDE5 in the presence or absence of a PDE5 inhibitor, MY5445, was shown (see Method for details). Basal level PDE activity
determined with extract from cells carrying pSNAP-tag(T7) was subtracted. The error bars indicate standard deviation (n=4).
doi:10.1371/journal.pone.0019922.g002
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fact, Vandeput et al have shown differences in Sildenfil inhibition
of cGMP-hydrolytic activity between human and mouse that could
be due to interactions of other members in the cGMP specific PDE
sub-family [33]. Based on these considerations, we feel there are
advantages for using larger mammals, including felines, to gain
insights into pathologic myocardial adaptations in humans.
We studied PDE5 expression under hypertrophic conditions, and
observed chamber-dependent differential expression of PDE5. Our
finding of reduced PDE5 levels in the LV of the Ao-banded animals
is consistent with the result by Senzaki et al using a tachypacing
canine model to induce LV failure [34]. The somewhat surprising
findings of increased PDE5 expression in the RV of Ao-banded
animals, coupled with the observation that in PA-banded animals
PDE5 expression was reduced in the LV but unchanged in the RV,
suggests that hemodynamic overload could induce chamber-
dependent factors in regulating PDE5 expression in the heart.
These chamber-dependent factors, upon sensing the stress due to
hemodynamic overload, could lead to differential responses from
thedownstream pathways intheRVandLV.Althoughdecreasesin
cGKI, a downstream effector of cGMP, were observed in
association with increases in RV PDE5 in the PA-banding model,
decreases in PDE5 in the LV were not paralleled by increases in
cGKI. Dissociation of RV and LV PDE5 expression and an
inconsistent relationship between PDE5 and cGKI expression
provided further evidence that the signal transduction pathways
involving PDE5 during cardiac hypertrophy could be regulated
differently in the two chambers, as recently suggested by others
commenting on incongruent responses to in vivo PDE5 inhibition
[16,35]. Moreover, Schafer et al. reported that beneficial effects of
PDE5inhibitionwasdependentonwhetherthe RVremodelingwas
achieved through monocrotaline-induced pulmonary hypertension
or PA banding, with the latter not benefiting from the inhibition of
PDE5 [14]. Other studies also indicated that beneficial effects of
PDE5 inhibition were dependent on the pressure-overload
magnitude, suggesting the possibility that differences in chamber
geometry may modulate the effects of a fixed resistance [15].
Conceivably, differences in the embryologic origins of the RV and
LV and/or chamber-specific distinctions in the isoforms of
functionally important transcription factors [36] could produce
differences in the RV and LV responses to seemingly equivalent
pathological stress. Regardless of the mechanism, our findings
contribute to a growing body of evidence demonstrating that the
right and left ventricles, with their distinct developmental origins,
may adopt different mechanisms to adapt to pathological stress,
including hemodynamic overload. The differential regulation of
Figure 3. Detection of PDE5 expression in myocytes of feline RV by IHC staining. Consecutive paraffin embedded RV tissue sections from
control feline hearts were used to examine PDE5 expression. The section in a) was incubated first with a rabbit polyclonal anti-PDE5 antibody
followed by HRP conjugated anti-rabbit secondary antibody and then developed using ImmPACT NovaRED as a substrate to visualize the bonded
antibodies. Section b) was processed in parallel with a) but omitted the primary anti-PDE5 antibody. Hematoxylin QS was used as nuclear
counterstaining.
doi:10.1371/journal.pone.0019922.g003
Figure 4. Detection of cGMP specific PDE activities in feline
cardiac tissues. Tissue homogenates from RV and LV of control
animals were prepared as described in Methods. cGMP specific PDE
activity in these samples were measured in the presence or absence of
120 uM MY5445, a specific inhibitor of PDE5, as described in Methods.
The error bars indicate standard deviation (n=4).
doi:10.1371/journal.pone.0019922.g004
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beofimportantphysiologicalsignificance,althoughtheexactnature
is not clear at this time. Further understanding of the detailed
molecular mechanism of the chamber specific regulation of PDE5
expression and its functional consequences will help us understand
the physiological significance.
In conclusion, the study of PDE5 and cGKI expression in the
RV and LV after Ao and PA banding in felines indicated that
PDE5 protein expression in the two chambers responded
differently, suggesting heterogeneity in the regulation of cGMP/
cGKI in hypertrophy. Accordingly, the pathogenic role of changes
in PDE5 expression and the impact of therapeutic PDE5
inhibition may well differ for right and left ventricles and with
different disease etiologies.
Materials and Methods
Ethics Statement
The investigation conformed to the Guide of the Care and Use of
Laboratory Animals published by the US National Institutes of
Health (NIH Publication No. 85-23, revised 1996), and all
protocols were approved by the appropriate institutional animal
care and use committees.
Chemicals and Reagents
All chemicals were purchased from Sigma-Aldrich (St. Louis,
MO, USA) unless otherwise indicated. Rabbit-polyclonal antibody
against human PDE5 was from Cell Signaling (Danvers, MA) and
rabbit-polyclonal antibodies against cGKI and GAPDH were
from Santa Cruz Biotechnology (Santa Cruz, CA). All the
secondary antibodies were from Jackson ImmunoResearch
Laboratories, Inc. (West Grove, PA). MY5445, 1-(3-chloropheny-
lamino)-4-phenylphthalazine, was purchased from Santa Cruz
Biotechnology.
Isolation of Aortic Smooth Muscle Cells and cDNA Library
Preparation
Aortic smooth muscle cells were isolated by an enzyme digestion
method [37]. Briefly, about 2 cm feline aorta was removed and
Figure 5. Determination of PDE5 expression in feline hypertrophy models. Tissue homogenates from LV and RV of control, PA-banded and
Ao-banded animal models were analyzed for PDE5 expression by immunoblotting. (a) Homogenates from LV samples. (b) Homogenate from RV
samples. Samples from control, PA-banded and Ao-banded groups were indicated in the figure. E. coli extracts from strains carrying pT7-PDE5 and
pSNAP-tag(T7) were used as positive and negative controls (shown as+and -). GAPDH levels in the same set of tissue samples were also determined
by immunoblotting, and used for normalization of PDE5 levels. (c) Normalized average PDE level in LV tissues from each group (n=4). (d) Normalized
average PDE level in RV tissues from each group. The error bars indicate standard deviations. Student t-test p values that show statistical significance
are indicated in the figure.
doi:10.1371/journal.pone.0019922.g005
Table 1. Cardiac Morphology at 1 Month after Banding.
HW/BW (mg/g) RV th (mm) IVS th (mm) PW th (mm) LVEDD (mm) LV FS (mm) LV Mass (mm)
Controls (1 mo.) 5.660.4 1.560.1 3.260.1 3.560.2 8.160.5 5866 2.860.3
Ao-Banded (1 mo.) 11.960.4* 2.260.2* 6.460.2* 7.660.6* 10.160.4* 43611 1 . 2 61.1*
PA-Banded (1 mo.) 9.160.7* 3.960.4* 4.360.5 4.260.4 7.460.3 4464 3.660.5
Values are mean 6 SEM.
Abbreviations: HW/BW-heart weight to body weight ratio; RV th-RV free wall thickness; IVS th-thickness of interventricular septum; PW th-thickness of left ventricular
posterior wall; LVEDD-left ventricular end-diastolic dimension; LVFS-left ventricular fractional shortening; LV Mass-calculated left ventricular mass (see text for details).
*p,0.05 vs. Control.
doi:10.1371/journal.pone.0019922.t001
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2 mm/side) before subjecting it to collagenase type II (Worthing-
ton Biochemical Corp., Lakewood, NJ) digestion at 180 U/ml in
DMEM/10% FBS at 37uC under sterile conditions. After 4 hours,
dissociated cells were removed and harvested by centrifugation at
5006 g. The cells were immediately seeded and cultured in
DMEM/10% FBS under 5% CO2. The cell type was subse-
quently confirmed by immunofluorescence using a mouse
monoclonal antibody against smooth muscle alpha actin (Sigma-
Aldrich). A cDNA library was generated by first isolating total
RNA from these cells using TRIzol (Invitrogen, Carlsbad, CA),
then by reverse transcription using Superscript II (Invitrogen)
according to the manufacturer’s instructions.
Isolation of PDE5 cDNA of Feline Origin
The internal and 39- sequence of PDE5 cDNA were obtained
from the smooth muscle cDNA library by PCR, using primers:
forward 59-TCAATGCAGAAGTTGACCAA and reverse 59-
GTTTCATCTGGAAGTTCTGC for the internal sequence
and forward 59-GTCACACTGGAGGTTCTGTC and reverse
59-AAAATACAGCAGTGGCAAAG for the 39- end sequence.
The 59- end of the cDNA was obtained by rapid amplification of
cDNA ends (RACE), using SMART RACE cDNA Amplification
kit (Clontech, Mountain View, CA) according to the manufactur-
er’s instructions. Specifically, total RNA isolated from the smooth
muscle cells were used for generating a RACE library. To amplify
cDNA fragments from the RACE library corresponding to the 59-
end of PDE5, a universal primer provided in the kit served as the
forward primer and a gene specific primer 59-GAATGTCCCAC-
CATTTCCCG served as the reverse primer. Three fragments
with the length of ,400, 1024 and ,1050 bases were obtained
and all three were sequenced. Based on the obtained sequence
data, primers were designed to amplify the full-length cDNA
(forward 59-AAGCAGTGGTATCAACGCAGAGT and reverse
59-AAAATACAGCAGTGGCAAAG) that spanned the open
reading frame (ORF). The sequence of all the fragments were
used to assemble contigs that represents an entire PDE5 ORF and
part of the 59 and 39 untranslated region.
Bacterial Expression of Feline PDE5 cDNA and
Preparation of Cell Extracts
A DNA fragment containing the complete ORF of PDE5 was
obtained by PCR using primers: forward 59-GAAATGGT-
CAATGCCTGGTTTG and reverse 59- ACTCAGTTCC-
GCTTGGCCTG with the full length cDNA from 2.3 as the
template. The PCR product was cloned into a TA cloning vector,
pGEMT-easy (Promega Corporation, Madison, WI). Several
clones were sequenced to select ones that were devoid of mutations
introduced during the PCR. A NdeI/EcoRI fragment of a
mutation-free clone was then excised for sub-cloning into an E.
coli expression vector pSNAP-tag(T7) (New England Biolabs,
Ipswich, MA) at NdeI and EcoRI site. The vector was transformed
into E. coli expression strain BL21-AI (Invitrogen). Expression of
PDE5 was induced by adding arabinose to 0.1% final concentra-
tion at 37uC when the E. coli culture density reached 0.3 O.D and
the induction duration was 3 hr. The cells were harvested and
lysed by sonication in 10 mM Tris buffered saline, pH 7.4 (TBS)
containing protease inhibitors (1 mM PMSF/protease inhibitor
cocktail (Sigma-Aldrich)). Cell debris was removed by centrifuga-
tion and glycerol was added to the extract at a final concentration
of 15%. The extracts were then stored at 280uC. Protein contents
in the samples were quantified using BCA Protein Assay (Thermo
Fisher Scientific Inc., Rockford, IL) and integrities were verified by
Coomassie G-250 staining. Briefly, after electrophoresis, the gel
was rinsed in water before incubating in a staining solution (0.1%
Coomassie Blue R-250/10% methanol/10% acetic acid) for 1 hr.
The gel was then de-stained in a solution containing 10% acidic
acid/10% methanol for 2 hours.
Figure 6. cGKI expression in feline hypertrophy models. Tissue homogenates from LV (a) and RV (b) of control, PA-banded and Ao-banded
animal models were analyzed for cGKI expression by immunoblotting, as described in Figure 5. GAPDH levels in the same set of samples were used to
normalize the cGKI levels. The normalized average cGKI levels in each group (n=4) are shown in (c) for LV and (d) in RV. The error bars indicate
standard deviations. Student t-test p values that show statistical significance are indicated in the figure.
doi:10.1371/journal.pone.0019922.g006
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PDE activity of the E. coli cell extracts was measured using a
cyclic nucleotide phosphodiesterase assay kit (Enzo Life Sciences
International, Inc., Plymouth Meeting, PA) according to the
manufacturer’s instructions. In each reaction, an extract sample
containing about 8 ug of total E. coli protein was used for the assay.
To measure enzyme activity of feline cardiac tissue samples,
extracts were first made by homogenizing cardiac tissue samples in
TBS containing protease inhibitors (1 mM PMSF/protease
inhibitor cocktail (Sigma-Aldrich)). After removing debris by
centrifugation at 10,0006 g, glycerol was added to a final
concentration of 15%. The extracts were then aliquoted and
stored at 280uC until assaying. Tissue extracts containing 15 mgo f
total protein were used in assay reaction. MY5445 was added to a
final concentration of 120 mM, as a PDE inhibitor, when
necessary.
Feline Model for Cardiac Hypertrophy
The animal models were created using a previously reported
protocol [38]. Briefly, after anesthesia induction with ketamine
(50 mg/kg) and acepromazine (0.5 mg/kg), young cats (8–10
weeks old) were intubated and ventilated with room air and 1%
isoflurane to maintain a surgical plane of anesthesia. Using aseptic
technique, a right thoracotomy and pericardiotomy were per-
formed and the pulmonary artery was dissected free from the
aorta. A 3.0 mm (internal diameter) clip was then placed around
the proximal pulmonary artery (PA) for the PA banding model or
around the ascending aorta (Ao) for the Ao banding model. The
lungs were fully expanded and the chest was closed. We used only
age-matched non-operated animals as controls in this study.
Echocardiography
Two-dimensional and M-mode echocardiography was per-
formed using an Acuson Cypress hand-held echocardiographic
platform with a 7V3c transducer. All animals were sedated with an
intramuscular injection of Ketamine (50 mg/kg) and Aceproma-
zine (0.5 mg/kg) prior to echocardiography. Short-axis M-mode
displays were used to measure the thickness of the right ventricular
free wall, interventricular septum (IVS), and left ventricular
posterior wall (PW) and the left ventricular dimensions at end-
diastole (LVEDD) and end-systole (LVESD). All measurements
were made in triplicate and averaged. Left ventricular fractional
shortening (LV FS) was calculated as:
LV FS~(LVEDD-LVESD)=LVEDD
Left ventricular mass (grams) was estimated using the formula
validated by Devereux et al [39].
Left ventricular mass~
0:8|1:04|½(IVSzLVEDDzPW)
3{(LVEDD)
3 
Immunohistochemistry and Immunoblotting (IB)
Isolated right ventricular tissues from control felines were
immediately fixed in 4% formaldehyde followed by paraffin-
embedding. Immunohistochemical staining was carried out using
a rabbit anti-human PDE5 antibody and the ImmPRESS Reagent
anti-rabbit Ig (Vector Laboratories, Burlingame, CA) according to
the manufacturer’s instructions. Briefly, sections were de-paraffi-
nized and re-hydrated. A citrate buffer, 10 mM citric acid, 0.05%
Tween 20, pH 6.0, was used to unmask antigens at 100uC for 209
and the endogenous peroxides was quenched by incubating the
sections in PBS/2% H2O2 for 159 at RT. After blocking with 2.5%
normal horse blocking serum, PDE5 expression in the tissue was
detected with the anti-human PDE5 and HRP-conjugated
secondary antibodies. ImmPACT Nova RED (Vector Laborato-
ries) was used to visualize PDE5 staining and hematoxylin QS
(Vector Laboratories) was used for nuclear counterstaining.
Background controls employed only the secondary antibody.
The stained sections were mounted in CitraMount Medium
(Polysciences, Inc., PA). Previously described protocol for IB was
used [40]. Briefly, flash-frozen RV and LV tissues were
homogenized in PBS/protease inhibitors (1 mM PMSF/protease
inhibitor cocktail (Sigma-Aldrich)) and debris removed by
centrifugation. Tissue extracts were then mixed with Lammli
buffer and loaded onto an 8% polyacrylamide gel. After
electrophoresis, the proteins were transferred to a PVDF
membrane and blocked with 5% non-fat dry milk. The membrane
was then incubated with a rabbit polyclonal anti-PDE5 or anti-
GAPDH antibodies followed by incubation with a secondary
HRP-conjugated goat anti-rabbit secondary antibody. The
membrane was washed with PBS/0.1% Tween-20 between each
incubation step. Secondary antibodies bound to the membranes
were detected by ECL substrate and visualized after exposure to x-
ray films.
Statistical Analysis
A one-way between subjects ANOVA was conducted to
compare the Control, PA-Banded and Ao-Banded subjects. Post
hoc comparisons using the Bonferroni-Holm test were used to
examine pairwise comparisons.
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